Suzuken Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 4 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Major Holders
Updated 2026/01/11| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Columbia Fd.s Varbl Series TRT II-Columbia Varbl PORT. - Overseas Core
|
1.2M | -5.85% | |
|
John Hancock Investment Trust-Disciplined Value International Fund
|
1.2M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
852.6K | -1.12% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
540.9K | +0.43% | |
|
Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund
|
425.4K | +2.31% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
411.3K | 0.00% |
Dividend History 3Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥100 | +11.1% |
| 2024 | ¥90 | +18.4% |
| 2023 | ¥76 | +5.6% |
| 2022 | ¥72 | 0.0% |
| 2021 | ¥72 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,239,112M | ¥2,314,828M | ¥2,386,493M | ¥2,399,952M |
| Gross Profit | ¥167,332M | ¥179,694M | ¥185,249M | ¥192,231M |
| Operating Income | ¥20,116M | ¥32,605M | ¥34,876M | ¥37,125M |
| Pretax Income | ¥22,535M | ¥30,636M | ¥42,836M | ¥50,328M |
| Net Income | ¥14,393M | ¥20,345M | ¥29,016M | ¥34,496M |
| EPS | ¥163.19 | ¥236.47 | ¥357.88 | ¥454.58 |
| Operating Margin | 0.90% | 1.41% | 1.46% | 1.55% |
| Balance Sheet | ||||
| Total Assets | ¥1,141,717M | ¥1,146,097M | ¥1,228,686M | ¥1,113,831M |
| Total Equity | ¥417,686M | ¥411,208M | ¥416,306M | ¥407,291M |
| Total Liabilities | ¥724,031M | ¥734,889M | ¥812,380M | ¥706,540M |
| Cash | ¥141,377M | ¥109,026M | ¥181,830M | ¥102,655M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 36.58% | 35.88% | 33.88% | 36.57% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥9,520M | ¥37,270M | ¥87,216M | -¥65,079M |
| Investing CF | ¥1,439M | -¥46,361M | ¥10,350M | ¥20,378M |
| Financing CF | -¥11,599M | -¥26,219M | -¥31,716M | -¥35,483M |
| Free CF | -¥4,772M | ¥19,528M | ¥71,576M | -¥83,726M |
| Efficiency | ||||
| ROE | 3.45% | 4.95% | 6.97% | 8.47% |
| ROA | 1.26% | 1.78% | 2.36% | 3.10% |
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥5,880
Rating Score: - (Based on 4 analysts)
※1=Strong Buy, 5=Strong Sell
Suzuken Co Ltd: Quiet Rally In Japan’s Healthcare Supply Chain Tests Investor Nerves - AD HOC NEWS ↗
Company Information
About
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the distribution of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution, Healthcare Product Development, Community Healthcare and Nursing Care Support, and Healthcare Related Services. The Pharmaceutical Distribution Business segment purchases ethical drugs, diagnostic agents, medical equipment, medical materials, and medical food products, as well as pharmaceutical and medical equipment manufacturers, and supplies medical institutions, and insurance pharmacies. The Healthcare Product Development segment offers ethical drugs, diagnostic reagents, and medical devices and materials. The Community Healthcare and Nursing Care Support segment provides a range of pharmacy and nursing care services. The Healthcare Related Services segment offers contract distribution for manufacturers and contract distribution of orphan drugs. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.
